AstraZeneca Announces $50 Billion Investment in U.S. Manufacturing and Research
By Ahmed Aboulenein and Maggie Fick
In response to President Donald Trump’s tariff policies, AstraZeneca has revealed plans to invest $50 billion in expanding manufacturing and research capabilities in the United States by 2030. This significant investment will support the construction of a new drug manufacturing facility in Virginia and the expansion of research and development (R&D) and cell therapy manufacturing in several states including Maryland, Massachusetts, California, Indiana, and Texas.
The pharmaceutical company also intends to upgrade its U.S. clinical trial supply network and continue investing in the development of novel medicines. AstraZeneca’s CEO, Pascal Soriot, stated that this expansion aligns with the company’s goal to achieve $80 billion in annual revenue by 2030, with half of that revenue stemming from the U.S. market.
Prior to Trump’s return to office, the U.S. accounted for over 40% of AstraZeneca’s annual revenue in 2024. The company had already been focusing on the U.S. market, which is valued at $635 billion, but Trump’s trade policies have prompted AstraZeneca to further prioritize its presence in the country.
The decision to bolster its U.S. footprint follows Trump’s calls for pharmaceutical companies to increase domestic manufacturing and reduce reliance on imported products. Trump has emphasized the need for drug prices in the U.S. to align with prices in other countries, asserting that the U.S. should not bear the burden of research and development costs for the global market.
The U.S. Commerce Secretary, Howard Lutnick, is leading an investigation into pharmaceutical imports that could potentially lead to the implementation of new tariffs. AstraZeneca welcomed the administration’s focus on ending the country’s dependency on foreign pharmaceutical products.
AstraZeneca’s $50 billion investment in the U.S. mirrors similar commitments made by other pharmaceutical giants such as Roche, Eli Lilly & Co, Johnson & Johnson, Novartis, and Sanofi. The company’s expansion plans are anticipated to create thousands of new jobs, with the new Virginia facility being the largest single manufacturing investment by AstraZeneca. This facility will produce active ingredients for the company’s experimental weight-loss medicines.
While AstraZeneca has faced challenges such as scrapping plans for a vaccine manufacturing plant in England due to reduced government support, the company remains committed to strengthening its presence in the U.S. market. Additionally, there have been reports suggesting that AstraZeneca may consider relocating its stock market listing from London to the U.S., although the company has not confirmed these speculations.
As AstraZeneca continues to make strategic investments to bolster its manufacturing and research capabilities in the U.S., the pharmaceutical industry as a whole is adapting to the evolving policy landscape under the Trump administration. With a focus on enhancing domestic production and competitiveness, AstraZeneca’s $50 billion investment underscores its commitment to driving innovation and growth in the U.S. pharmaceutical market.
